Market Overview

UPDATE: Canaccord Genuity Decreases PT on Delcath Systems to $5

Share:
Related DCTH
25 Biggest Mid-Day Gainers For Friday
Mid-Afternoon Market Update: Dow Rises More Than 200 Points; Lexmark Shares Spike Higher

According to a research report this morning, Canaccord Genuity decreases its PT on Delcath Systems (NASDAQ: DCTH) from $8 to $5.

Canaccord Genuity explained, ‘These physicians provided an interesting perspective about how CHEMOSAT fits in the oncology armamentarium. We reduce our forward estimates and price target – to $5.00 from $8.00 – to reflect dilution related to the recent equity offering and previously announced delay of the NDA filing (mid-August-E).”

Delcath Systems closed Friday at $1.44 as Canaccord Genuity maintains its Buy rating.

Latest Ratings for DCTH

DateFirmActionFromTo
Mar 2016WallachbethInitiates Coverage onBuy
May 2013Cowen & Co.DowngradesOutperformUnderperform
May 2013Roth CapitalDowngradesBuySell

View More Analyst Ratings for DCTH
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Reiteration Analyst Ratings

 

Related Articles (DCTH)

View Comments and Join the Discussion!